Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Esophageal candidiasis treatment

Caspofungin is indicated in the treatment of invasive aspergillosis in patients refractory to, or intolerant of, other antifungal therapies empirical treatment for presumed fungal infections in febrile, neutropenic patients treatment of esophageal candidiasis treatment of candidemia and the following Candida infections intra-abdominal abscesses, peritonitis, and pleural space infections. [Pg.136]

Recognize when topical versus oral treatment is indicated for a patient with oropharyngeal candidiasis, esophageal candidiasis, and fungal skin infections. [Pg.1199]

Two to three weeks of fluconazole or itraconazole solution are highly effective and demonstrate similar clinical response rates.32 Doses of 100 to 200 mg are effective in immunocompetent patients but doses up to 400 mg are recommended for immunocompromised patients. Due to variable absorption, ketoconazole and itraconazole capsules should be considered second-line therapy. In severe cases, oral azoles may prove ineffective, warranting the use of amphotericin B for 10 days. Although echinocandins and voriconazole are effective in treatment of esophageal candidiasis, experience remains limited. [Pg.1205]

If the patient has had oropharyngeal or esophageal candidiasis previously, determine what treatments were helpful to the patient in the past. [Pg.1206]

If immunocompromised patients experience frequent or severe recurrences, particularly of esophageal candidiasis, chronic maintenance therapy with fluconazole 100 to 200 mg daily should be considered. In patients with infrequent or mild cases, secondary prophylaxis is not recommended. The rationale for not giving prophylaxis includes availability of effective treatments for acute episodes, risk of developing resistant organisms, potential for drug interactions, and the cost of therapy. [Pg.1206]

Although more invasive, esophageal candidiasis does not typically evolve into a life-threatening infection. However, topical therapy is ineffective. Azoles (fluconazole, itraconazole solution, or voriconazole), echinocandins, or intravenous amphotericin B (in cases of unresponsive infections) are effective treatment options. Parenteral therapy should be used in patients who are unable to take oral medications.20... [Pg.1223]

Dowell JA, Stogniew M, Krause D, Henkel T. (2003) Anidulafungin (ANID) pharmacokinetic (PK)/Pharmacodynamic (PD) correlation Treatment of esophageal candidiasis. 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy Abstract A-1578. [Pg.137]

Use primarily for treatment of patients with progressive and potentially fatal fungal infections. Do not use to treat noninvasive forms of fungal disease such as oral thrush, vaginal candidiasis, and esophageal candidiasis in patients with normal neutrophil counts. [Pg.1663]

Onychomycosis (capsules only) Treatment of onychomycosis of the toenail with or without fingernail involvement and onychomycosis of the fingernail because of dermatophytes Tinea unguium) in nonimmunocompromised patients. Oropharyngeal/esophageal candidiasis (oral solution only) Treatment of oropharyngeal or esophageal candidiasis. [Pg.1683]

Esophageal candidiasis - 100 mg/day for a minimum treatment of 3 weeks. Continue treatment for 2 weeks following resolution of symptoms. Doses up to 200 mg/day may be used based on medical judgment of the patient s response to therapy. Vigorously swish the solution in the mouth (10 mL at a time) for several seconds and swallow. [Pg.1684]

Severely neutropenic patients Itraconazole oral solution as treatment for oropharyngeal and/or esophageal candidiasis was not investigated in severely neutropenic patients. Because of its pharmacokinetic properties, itraconazole oral solution is not recommended for initiation of treatment in patients at immediate risk of systemic candidiasis. [Pg.1687]

For the treatment of patients with esophageal candidiasis, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation (HSCT). [Pg.1694]

Treatment of esophageal candidiasis-Prophylaxis of Candida infections in HSCT recipients-... [Pg.1694]

In patients treated successfully for esophageal candidiasis, the mean duration of treatment was 15 days (range, 10 to 30 days). [Pg.1694]

Nystatin (Mycostatin) is a polyene antifungal drug with a ring structure similar to that of amphotericin B and a mechanism of action identical to that of amphotericin B. Too toxic for systemic use, nystatin is limited to the topical treatment of superficial infections caused by C albicans. Infections commonly treated by this drug include oral candidiasis (thrush), mild esophageal candidiasis, and vaginitis. [Pg.598]

Fluconazole is very effective in the treatment of infections with most Candida spp. Thrush in the end-stage AIDS patient, often refractory to nystatin, clotrimazole, and ketoconazole, can usually be suppressed with oral fluconazole. AIDS patients with esophageal candidiasis also usually respond to fluconazole. A single 150-mg dose has been shown to be effective treatment for vaginal candidiasis. A 3-day course of oral fluconazole is effective treatment for Candida urinary tract infection and is more convenient than amphotericin B bladder irrigation. Preliminary findings suggest that Candida endophthalmitis can be successfully treated with fluconazole. Stable nonneutropenic patients with candidemia can be adequately treated with fluconazole, but unstable, immunosuppressed patients should initially receive... [Pg.598]

Indications Treatment of oropharyngeal and esophageal candidiasis and may be effective for the treatment of serious systemic candidal infections Cryptococcal meningitis c <... [Pg.59]

Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, Smietana JM, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002 113(4) 294-9. [Pg.1200]

The efficacy, safety, and tolerability of voriconazole and fluconazole have been compared in 391 immunocompromised adults with esophageal candidiasis in a randomized, double-blind, multicenter trial (11). Most of the patients (94%) had AIDS. Following randomization, they took either voriconazole (200 mg bd) or fluconazole (400 mg on day 1 followed by 200 mg od) for a median of 14 or 15 days respectively. Treatment was continued for 7 days after the resolution of aU signs and symptoms but was not allowed to exceed 42 days. The two drugs achieved comparable success rates (98% voriconazole, 95% fluconazole), as assessed by esophagoscopy in the primary efficacy analysis in 256 patients. More patients discontinued voriconazole because of laboratory test abnormalities (3.5 versus 1%) or treatment-related adverse events (2.5 versus 0.5%). The most frequent... [Pg.3689]

Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ Esophageal Candidiasis Study Group. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of... [Pg.3691]

Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients Treatment issues. Clin Infect Dis 1998 26 259-274. [Pg.2159]

Arathoon EG, Gotuzzo E, Noriega EM, et al. Randomized, doubleblind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002 46 451-457. [Pg.2160]


See other pages where Esophageal candidiasis treatment is mentioned: [Pg.1199]    [Pg.1205]    [Pg.513]    [Pg.33]    [Pg.1671]    [Pg.1691]    [Pg.76]    [Pg.1062]    [Pg.464]    [Pg.198]    [Pg.1198]    [Pg.1199]    [Pg.1199]    [Pg.130]    [Pg.130]    [Pg.2151]    [Pg.2152]    [Pg.2153]    [Pg.2154]    [Pg.2154]    [Pg.2155]    [Pg.2270]    [Pg.274]    [Pg.275]    [Pg.367]   
See also in sourсe #XX -- [ Pg.1204 , Pg.1205 , Pg.1223 ]

See also in sourсe #XX -- [ Pg.2151 , Pg.2152 , Pg.2152 , Pg.2153 , Pg.2154 , Pg.2266 ]




SEARCH



Candidiasis

Candidiasis treatment

Esophageal

Esophageal candidiasis

Esophagitis

© 2024 chempedia.info